VRDN: Viridian Therapeutics Inc

VRDN新闻

• 14:13 Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy
• 13:32 RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38
• 13:32 RBC Capital维持对Viridian Therapeutics的跑赢市场评级，将目标股价上调至38美元
• 14:46 Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN)
• 14:41 VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
• 10:21 Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-07-01
• 18:12 Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
• 13:24 Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Virid
• 09:42 Nasdaq futures lead Wall St higher as Middle East tensions ease
• 05:23 Viridian Therapeutics (VRDN): Two-Step TED Franchise With More Leverage Than Market Likes
• 04:02 Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• 00:05 Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-05-09